Schechter Investment Advisors LLC Has $1.28 Million Stake in Koninklijke Philips (NYSE:PHG)

Schechter Investment Advisors LLC decreased its holdings in shares of Koninklijke Philips (NYSE:PHG) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,701 shares of the technology company’s stock after selling 5,755 shares during the quarter. Schechter Investment Advisors LLC’s holdings in Koninklijke Philips were worth $1,276,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Koninklijke Philips by 4.9% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 16,411 shares of the technology company’s stock valued at $501,000 after buying an additional 771 shares during the period. Bank of New York Mellon Corp boosted its holdings in Koninklijke Philips by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 62,767 shares of the technology company’s stock worth $1,916,000 after purchasing an additional 1,414 shares during the last quarter. Cetera Advisor Networks LLC acquired a new position in Koninklijke Philips during the first quarter worth $311,000. Citigroup Inc. boosted its holdings in Koninklijke Philips by 1.3% during the first quarter. Citigroup Inc. now owns 36,882 shares of the technology company’s stock worth $1,126,000 after purchasing an additional 483 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in Koninklijke Philips by 9.9% during the first quarter. Bank of Montreal Can now owns 94,798 shares of the technology company’s stock worth $3,002,000 after purchasing an additional 8,515 shares during the last quarter. Institutional investors and hedge funds own 13.67% of the company’s stock.

Koninklijke Philips Price Performance

NYSE:PHG opened at $20.32 on Thursday. Koninklijke Philips has a 52 week low of $16.18 and a 52 week high of $24.27. The firm’s 50-day simple moving average is $21.00 and its 200 day simple moving average is $20.93. The company has a quick ratio of 0.78, a current ratio of 1.20 and a debt-to-equity ratio of 0.58.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings results on Monday, January 29th. The technology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Koninklijke Philips had a negative net margin of 2.53% and a positive return on equity of 14.17%. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.47 billion. On average, analysts forecast that Koninklijke Philips will post 1.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PHG has been the subject of a number of recent analyst reports. BNP Paribas cut shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research note on Wednesday, February 7th. StockNews.com upgraded shares of Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.